CN104491839A - 丝氨酸蛋白酶抑制剂b3用于治疗痛风性肾病的用途 - Google Patents
丝氨酸蛋白酶抑制剂b3用于治疗痛风性肾病的用途 Download PDFInfo
- Publication number
- CN104491839A CN104491839A CN201410699345.0A CN201410699345A CN104491839A CN 104491839 A CN104491839 A CN 104491839A CN 201410699345 A CN201410699345 A CN 201410699345A CN 104491839 A CN104491839 A CN 104491839A
- Authority
- CN
- China
- Prior art keywords
- gouty nephropathy
- protease inhibitor
- serine protease
- nephropathy
- gouty
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010046337 Urate nephropathy Diseases 0.000 title claims abstract description 38
- 238000011282 treatment Methods 0.000 title claims abstract description 12
- 239000003001 serine protease inhibitor Substances 0.000 title abstract description 9
- 229940122055 Serine protease inhibitor Drugs 0.000 title abstract 7
- 101710102218 Serine protease inhibitor Proteins 0.000 title abstract 7
- 239000003814 drug Substances 0.000 claims abstract description 12
- 230000008021 deposition Effects 0.000 claims abstract description 6
- 210000005084 renal tissue Anatomy 0.000 claims abstract description 6
- 102100036383 Serpin B3 Human genes 0.000 claims description 21
- 101710156166 Serpin B3 Proteins 0.000 claims description 21
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 abstract description 8
- 238000002347 injection Methods 0.000 abstract description 5
- 239000007924 injection Substances 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 abstract description 2
- 230000002411 adverse Effects 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 4
- 150000007971 urates Chemical group 0.000 abstract 1
- 239000002390 adhesive tape Substances 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 208000017169 kidney disease Diseases 0.000 description 7
- 201000001431 Hyperuricemia Diseases 0.000 description 6
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 6
- 238000002349 difference gel electrophoresis Methods 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 229940116269 uric acid Drugs 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 5
- 239000003292 glue Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 201000005569 Gout Diseases 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000013399 early diagnosis Methods 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000010413 mother solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 208000036487 Arthropathies Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000012659 Joint disease Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010037596 Pyelonephritis Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102000008847 Serpin Human genes 0.000 description 2
- 108050000761 Serpin Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 208000019932 Aciduria Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 102100034612 Annexin A4 Human genes 0.000 description 1
- 108090000669 Annexin A4 Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 208000022182 gross hematuria Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000006101 laboratory sample Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical class [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 1
- 238000011617 nephropathy animal model Methods 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
蛋白点编号 | T-test检验 | 比率 | |
1 | 312 | 9.90E-06 | 4.63 |
2 | 545 | 9.90E-06 | -4.08 |
3 | 659 | 9.90E-06 | 3.12 |
4 | 681 | 9.90E-06 | 3.43 |
5 | 699 | 9.90E-06 | 2.83 |
6 | 1074 | 1.10E-05 | -2.54 |
7 | 548 | 1.60E-05 | 1.71 |
8 | 631 | 2.00E-05 | 4.54 |
9 | 502 | 2.10E-05 | -3.78 |
10 | 640 | 2.10E-05 | 3.25 |
11 | 670 | 2.40E-05 | -2.12 |
12 | 1153 | 2.40E-05 | 5.78 |
13 | 1197 | 2.40E-05 | 4.46 |
14 | 1095 | 2.60E-05 | 2.5 |
15 | 615 | 2.90E-05 | 3.09 |
16 | 717 | 2.90E-05 | 2.83 |
17 | 653 | 3.00E-05 | 3.54 |
18 | 700 | 3.00E-05 | 2.26 |
19 | 978 | 3.20E-05 | 2.41 |
20 | 599 | 3.30E-05 | 1.64 |
21 | 1097 | 3.70E-05 | 2.5 |
22 | 1020 | 4.40E-05 | 6.09 |
23 | 415 | 5.10E-05 | 3.78 |
24 | 629 | 5.30E-05 | 8.37 |
25 | 1054 | 5.60E-05 | -2.5 |
26 | 708 | 5.70E-05 | 4.33 |
27 | 568 | 6.10E-05 | -3.61 |
28 | 685 | 6.80E-05 | -12.34 |
29 | 738 | 7.40E-05 | 3 |
30 | 1001 | 7.40E-05 | -2.57 |
31 | 715 | 7.50E-05 | 4.2 |
32 | 419 | 8.10E-05 | 3.43 |
33 | 490 | 8.10E-05 | 2.48 |
34 | 435 | 8.80E-05 | 3.19 |
35 | 655 | 9.10E-05 | -2.64 |
36 | 507 | 9.40E-05 | 1.73 |
37 | 562 | 0.0001 | -2.41 |
38 | 1011 | 0.00011 | -1.82 |
39 | 795 | 0.00012 | -2.4 |
40 | 1129 | 0.00012 | -2.39 |
41 | 682 | 0.00014 | -2.94 |
42 | 426 | 0.00015 | 3.58 |
43 | 797 | 0.00015 | -2.27 |
44 | 1150 | 0.00016 | 3.52 |
45 | 561 | 0.00017 | 2.64 |
46 | 639 | 0.00018 | 3.13 |
47 | 626 | 0.00021 | -1.56 |
48 | 864 | 0.00021 | 1.57 |
49 | 1080 | 0.00021 | -2.26 |
50 | 1037 | 0.00026 | -2.12 |
51 | 617 | 0.00028 | 3.18 |
52 | 832 | 0.00031 | 1.6 |
53 | 1099 | 0.00031 | 2.32 |
54 | 596 | 0.00032 | 1.64 |
55 | 553 | 0.00035 | 2.49 |
56 | 1111 | 0.00035 | -5.04 |
57 | 746 | 0.00036 | -3.72 |
58 | 764 | 0.00046 | 1.94 |
59 | 1040 | 0.00046 | -2.72 |
60 | 632 | 0.00049 | 1.99 |
61 | 794 | 0.00049 | -2.02 |
62 | 600 | 0.00052 | 2.35 |
63 | 1064 | 0.00055 | -2.32 |
64 | 844 | 0.00057 | -1.82 |
65 | 686 | 0.0006 | -3.76 |
66 | 1036 | 0.00061 | -2.59 |
67 | 636 | 0.00071 | 2.31 |
68 | 704 | 0.00087 | 1.9 |
69 | 646 | 0.00092 | 1.63 |
70 | 863 | 0.00093 | 1.53 |
71 | 684 | 0.00099 | 2.96 |
72 | 616 | 0.001 | -2.04 |
73 | 789 | 0.0011 | -1.87 |
74 | 1003 | 0.0026 | -1.75 |
75 | 678 | 0.0028 | 2.32 |
76 | 642 | 0.003 | -1.61 |
77 | 512 | 0.0037 | 1.61 |
78 | 726 | 0.004 | -2.53 |
79 | 800 | 0.0054 | -1.5 |
80 | 724 | 0.0069 | -3.61 |
81 | 307 | 0.0073 | 1.82 |
82 | 518 | 0.011 | -2.12 |
83 | 1148 | 0.012 | -2.5 |
84 | 672 | 0.019 | -1.56 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410699345.0A CN104491839B (zh) | 2014-11-27 | 2014-11-27 | 丝氨酸蛋白酶抑制剂b3用于治疗痛风性肾病的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410699345.0A CN104491839B (zh) | 2014-11-27 | 2014-11-27 | 丝氨酸蛋白酶抑制剂b3用于治疗痛风性肾病的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104491839A true CN104491839A (zh) | 2015-04-08 |
CN104491839B CN104491839B (zh) | 2016-06-22 |
Family
ID=52933353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410699345.0A Expired - Fee Related CN104491839B (zh) | 2014-11-27 | 2014-11-27 | 丝氨酸蛋白酶抑制剂b3用于治疗痛风性肾病的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104491839B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113768865A (zh) * | 2020-11-04 | 2021-12-10 | 深圳前海鹰岗生物科技有限公司 | 一种抑制炎症因子释放治疗痛风急性发作的聚合物微针及制备方法 |
WO2023092768A1 (zh) * | 2021-11-24 | 2023-06-01 | 中南大学湘雅医院 | Serpinb3/b4作为靶点在玫瑰痤疮等炎症性皮肤病治疗药物中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103429236A (zh) * | 2011-03-11 | 2013-12-04 | 安成生物科技股份有限公司 | 治疗高尿酸血症和与高尿酸血症相关的代谢性病症的方法和组合物 |
-
2014
- 2014-11-27 CN CN201410699345.0A patent/CN104491839B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103429236A (zh) * | 2011-03-11 | 2013-12-04 | 安成生物科技股份有限公司 | 治疗高尿酸血症和与高尿酸血症相关的代谢性病症的方法和组合物 |
Non-Patent Citations (2)
Title |
---|
CLAIRE HEIT等: "update of the human and mouse SERPIN gene superfamily", 《HUMAN GENOMICS》, 31 December 2013 (2013-12-31), pages 1 - 14 * |
樊静: "丝氨酸蛋白酶抑制剂B亚家族", 《生命的化学》, 31 December 2003 (2003-12-31), pages 275 - 276 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113768865A (zh) * | 2020-11-04 | 2021-12-10 | 深圳前海鹰岗生物科技有限公司 | 一种抑制炎症因子释放治疗痛风急性发作的聚合物微针及制备方法 |
WO2023092768A1 (zh) * | 2021-11-24 | 2023-06-01 | 中南大学湘雅医院 | Serpinb3/b4作为靶点在玫瑰痤疮等炎症性皮肤病治疗药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN104491839B (zh) | 2016-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1601355B1 (en) | Diagnostic method for prevision of kidney transplantation rejection | |
CN104491839B (zh) | 丝氨酸蛋白酶抑制剂b3用于治疗痛风性肾病的用途 | |
CN102481327B (zh) | 一种龙眼核萃取物的制备方法与应用 | |
JP2015044836A (ja) | リュウガン種子抽出物の製造方法及びその応用 | |
CN103149361A (zh) | 犬早孕因子胶体金检测试纸卡及其制备方法和应用 | |
CN102706787B (zh) | 菁染料的新用途 | |
CN106177907A (zh) | Tenascin-C在制备诊断和治疗肾脏损伤制剂中的应用 | |
CN105456481B (zh) | 南五味子提取物在制备肝再生药物中的应用 | |
CN102018699B (zh) | Xyloketal B在制备调节血脂水平药物中的应用 | |
CN104034904A (zh) | 一种糖尿病肾病检测试纸 | |
RU2522238C1 (ru) | Способ диагностики нефротического синдрома с минимальными изменениями у детей | |
CN104147205B (zh) | 一种龙眼核萃取物的制备方法与应用 | |
Saleh et al. | Myocardial performance index in nephrotic syndrome | |
CN101317857A (zh) | 山羊颌下腺生物活性物质的提取方法与应用 | |
CN109730994A (zh) | 组蛋白甲基转移酶ezh2的抑制剂在制备防治腹膜透析后腹膜纤维化的药物中的用途 | |
KR20130089474A (ko) | Kim-1 단백질을 포함하는 개의 급성신장손상 진단용 바이오 마커 조성물 | |
CN104945506A (zh) | 一种用于乳腺癌诊断和预后判断的免疫组化试剂 | |
CN104945496A (zh) | 一种多肽及其在制备与纯化对ehd2特异的抗体中的应用 | |
CN203858250U (zh) | 一种d-二聚体检测试纸条 | |
CN102796804A (zh) | 一种特异性γ-谷氨酰基转移酶检测方法及其应用 | |
CN107982250A (zh) | 双氢青蒿素在治疗脓毒症诱导的急性肾损伤药物中的应用 | |
JP5946509B2 (ja) | リュウガン種子抽出物の製造方法及びその応用 | |
CN105116152B (zh) | 一种人源性尿液Endocan蛋白的ELISA检测试剂盒及检测方法 | |
WO2024065892A1 (zh) | 检测嗜酸性粒细胞的试剂、嗜酸性粒细胞及其胞质内容物和羟基二十二碳六烯酸的应用 | |
RU2429476C1 (ru) | Способ диагностики артроза |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Wang Yunlong Inventor after: Lu Shulai Inventor after: Jia Shaoyou Inventor after: Li Xiaoyu Inventor after: Yu Li Inventor after: Li Changgui Inventor before: Wang Yunlong |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160520 Address after: 266003 Shandong city of Qingdao province Jiangsu City Road No. 16 Applicant after: Affiliated Hospital of University Of Qingdao Address before: 266003 Shandong city of Qingdao province Jiangsu City Road No. 16 Applicant before: Wang Yunlong |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160622 Termination date: 20161127 |